Expert Ratings For Surgery Partners
Portfolio Pulse from Benzinga Insights
Surgery Partners (NASDAQ:SGRY) has been evaluated by 4 analysts over the last three months, showing a diverse range of opinions. Recent ratings indicate a shift towards a more bullish outlook, with an average 12-month price target of $44.25, reflecting a 2.91% increase from the previous target of $43.00. The company's financial overview reveals a solid revenue growth rate of 4.0% as of December 31, 2023, an impressive net margin, and strong financial health indicators such as ROE and ROA. Surgery Partners operates in healthcare services, focusing on outpatient surgical and ancillary care.
March 05, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surgery Partners has seen a positive shift in analyst ratings with an updated average price target of $44.25, indicating a bullish sentiment. The company's financial performance, including a 4.0% revenue growth and strong ROE and ROA, supports a positive outlook.
The increase in the average price target to $44.25, along with positive financial indicators such as a 4.0% revenue growth and strong ROE and ROA, suggests a bullish sentiment among analysts. This, combined with the company's strategic focus on outpatient surgical and ancillary care, positions SGRY for potential short-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100